Protagonist Therapeutics, Inc.
7707 Gateway Boulevard
Suite 140
Newark
California
94560
United States
Tel: 650-587-5766
Fax: n./a
Website: http://www.protagonist-inc.com/
Email: info@protagonist-inc.com
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs. Compared to injectable antibody drugs, Protagonist's oral peptides offer targeted delivery to the gastrointestinal (GI) tissue compartment, potential for improved safety due to minimal exposure in the blood, improved convenience and compliance due to oral delivery, lower cost, and an opportunity for earlier introduction of targeted therapy for inflammatory bowel disease (IBD). Protagonist's initial lead product candidates, PTG-100 and PTG-200, are based on this approach, and the company believes they have the potential to transform the existing treatment paradigm for IBD, a GI disease consisting primarily of ulcerative colitis and Crohn's disease.
YEAR FOUNDED:
2001
LEADERSHIP:
Founder: Mark Symythe
CEO: Dinesh Patel
CMO (Marketing): Richard Shames
CFO: Tom O’Neil
CSO (Scientific): David Liu
JOBS:
Please click here for Protagonist Therapeutics job opportunities.
CLINICAL TRIAL:
Please click here for clinical trial information.
233 articles about Protagonist Therapeutics, Inc.
-
Protagonist Therapeutics Expands PTG-200 Collaboration Agreement with Janssen to Include Second Generation Oral IL-23 Receptor Antagonists
5/8/2019
Protagonist Therapeutics, Inc. announced the expansion of its worldwide license and collaboration agreement with Janssen Biotech, Inc. for the co-development and commercialization of PTG-200, Protagonist's first-in-class, oral peptide IL-23 receptor antagonist, for all indications including inflammatory bowel disease (IBD).
-
Protagonist Therapeutics to Present Preclinical Data on PN-943 at Digestive Disease Week Conference 2019
5/7/2019
Oral plenary presentation to detail properties of oral, gut-restricted alpha-4-beta-7 integrin antagonist candidate PN-943
-
Protagonist Therapeutics to Present at the H.C. Wainwright & Co. Global Life Sciences Conference on Tuesday, April 9
4/1/2019
Protagonist Therapeutics, Inc. announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright & Co. Global Life Sciences Conference in London.
-
Protagonist Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
3/12/2019
Preliminary results from the Phase 2 TRANSCEND study of the hepcidin mimetic PTG-300 for the treatment of beta thalassemia expected in the second half of 2019
-
Protagonist Therapeutics to Announce Fourth Quarter and Full Year 2018 Financial Results
3/5/2019
Protagonist Therapeutics, Inc. will announce fourth quarter and year end 2018 financial results after the NASDAQ market closes on Tuesday, March 12, 2019.
-
Protagonist Therapeutics to Present at the Leerink Partners 8th Annual Global Healthcare Conference on Thursday, Feb. 28
2/21/2019
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Leerink Partners 8th Annual Global Healthcare Conference in New York.
-
Protagonist Therapeutics Reports Granting of Inducement Award to Suneel Gupta, Ph.D.
1/16/2019
Protagonist Therapeutics, Inc. reported that on Jan. 15, 2019, it issued an inducement award to Suneel Gupta, Ph.D., the Company's recently hired Executive Vice President of Clinical Operations and Pharmacology, in accordance with the terms of Dr. Gupta's employment offer letter.
-
Protagonist Therapeutics Initiates Phase 2 Trial of Novel Hepcidin Mimetic PTG-300 for the Treatment of Patients with Beta Thalassemia
1/9/2019
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the first patient has been dosed in the Phase 2 study of PTG-300, an injectable hepcidin mimetic peptide in development for the treatment of patients with beta thalassemia, a rare disease characterized by chronic anemia and iron overload.
-
Protagonist Therapeutics Appoints Suneel K. Gupta, Ph.D., as Executive Vice President of Clinical Operations and Pharmacology
1/7/2019
Protagonist Therapeutics, Inc. announced the appointment of Suneel Gupta, Ph.D., as Executive Vice President of Clinical Operations and Clinical Pharmacology
-
Protagonist Therapeutics Initiates Phase 1 Trial of Oral, Gut-Restricted, Alpha-4-Beta-7 Integrin Antagonist PN-10943
12/13/2018
PN-10943 begins clinical development as a potential novel oral therapy for patients with inflammatory bowel disease
-
Protagonist Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
12/5/2018
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference in New York.
-
Protagonist Therapeutics Announces New Development Candidate PN-10943 for the Treatment of Inflammatory Bowel Disease
11/27/2018
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced that the Company plans to begin clinical development of PN-10943, an oral, gut-restricted alpha-4-beta-7 integrin antagonist peptide for the treatment of inflammatory bowel disease (IBD)
-
Protagonist Therapeutics to Present at the Stifel 2018 Healthcare Conference Wednesday, Nov. 14
11/7/2018
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Stifel 2018 Healthcare Conference at 8:45 a.m. EST at the Lotte New York Palace Hotel.
-
Protagonist Therapeutics Announces Completion of Phase 1 Clinical Trial of Oral IL-23 Receptor Antagonist PTG-200
11/6/2018
Results in normal healthy volunteers provide safety, pharmacokinetic and pharmacodynamic data
-
Protagonist Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
11/6/2018
Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported its financial results for the third quarter ended September 30, 2018, and provided a corporate update on its clinical development programs.
-
Protagonist Therapeutics Presents Clinical Data from the PROPEL Study of PTG-100 in Ulcerative Colitis at United European Gastroenterology Week
10/22/2018
PTG-100 demonstrates signals of clinical efficacy and is well tolerated
-
Protagonist Therapeutics Announces Acceptance of Late Breaking Abstract for PTG-100 at the United European Gastroenterology Week Meeting
10/8/2018
Protagonist Therapeutics, Inc. today announced that Dr. William J. Sandborn will present clinical data from a Phase 2 study of PTG-100, the Company's oral, gut-restricted alpha-4-beta-7 integrin specific antagonist peptide that is being developed for treatment of ulcerative colitis, at the United European Gastroenterology Week meeting.
-
Protagonist Therapeutics Announces Fast Track Designation Granted by U.S. FDA to Hepcidin Mimetic PTG-300
9/27/2018
Designation applies to development for the treatment of chronic anemia in patients with beta-thalassemia
-
Protagonist Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference Monday, Oct. 1
9/24/2018
Protagonist Therapeutics, Inc. today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Cantor Fitzgerald Global Healthcare Conference at 4:40 p.m. at the InterContinental New York Barclay Hotel.
-
Protagonist Therapeutics Reports Granting of Inducement Award to Carter King
9/19/2018
Protagonist Therapeutics, Inc. today reported that on Sept. 15, 2018, it issued an inducement award to Carter King, the Company's recently hired Vice President of Business Development, in accordance with the terms of Mr. King's employment offer letter.